RecruitingNCT05704881

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

Monitoring of the End-tidal Carbon Dioxide (EtCO2 ) as a Severity Criterion in COPD Exacerbations: a Prospective Observational Study

Sponsor

University Hospital, Grenoble

Enrollment

240 participants

Start Date

Mar 3, 2023

Study Type

OBSERVATIONAL

Conditions

Pulmonary Disease, Chronic Obstructive Exacerbation Copd

Summary

Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether measuring the amount of carbon dioxide in exhaled breath (called end-tidal CO2, or EtCO2) can help emergency doctors quickly assess how serious a COPD flare-up is in patients who arrive at the emergency department with difficulty breathing. **You may be eligible if...** - You are 18 or older - You have come to the emergency department with sudden shortness of breath - You have a known or reported history of COPD (a chronic lung disease often caused by smoking) **You may NOT be eligible if...** - Your blood pressure is dangerously low upon arrival - You were already on a breathing machine (invasive or non-invasive ventilation) when you arrived - You have been in this study before - You do not speak French or have difficulty understanding or communicating - Your COPD diagnosis is ruled out after medical evaluation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEnd-Tidal CO2 measurement during COPD exacerbation

The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.